Standard Operating Procedure for Ensuring Data Integrity in Bioanalytical Laboratories during BA/BE Studies
| Department | BA-BE Studies |
|---|---|
| SOP No. | SOP/BA-BE/185/2025 |
| Supersedes | SOP/BA-BE/185/2022 |
| Page No. | Page 1 of 10 |
| Issue Date | 17/04/2025 |
| Effective Date | 20/04/2025 |
| Review Date | 17/04/2026 |
1. Purpose
To establish a comprehensive procedure for maintaining data integrity in all bioanalytical processes supporting bioavailability/bioequivalence (BA/BE) studies, ensuring compliance with regulatory standards and ALCOA+ principles.
2. Scope
This SOP applies to all personnel, electronic systems, data collection tools, and documentation processes within the bioanalytical laboratory involved in BA/BE studies.
3. Responsibilities
- Analysts: Ensure timely, complete, and accurate data
recording and follow Good Documentation Practices (GDP).
Data Reviewers: Verify data accuracy, authenticity, and traceability before approval.
System Administrators: Manage access control, backups, and audit trails in analytical software systems.
QA Unit: Conducts periodic audits for data integrity compliance and investigates deviations.
4. Accountability
The Head of Bioanalytical Laboratory is accountable for enforcing data integrity practices and ensuring ongoing adherence to regulatory expectations across all BA/BE studies.
5. Procedure
5.1 ALCOA+ Principles Implementation
- Ensure that all data generated meets the ALCOA+ criteria:
- Attributable: Clearly identify who performed the action.
- Legible: Data must be readable and permanent.
- Contemporaneous: Record data at the time of activity.
- Original: Maintain original source data.
- Accurate: Ensure correctness and reliability.
- Complete, Consistent, Enduring, Available – Additional (+) principles to support lifecycle integrity.
5.2 Data Entry and Review
- Ensure all data entries in logbooks, software, and LIMS are dated, signed, and attributable to the person performing the activity.
- Use ink for handwritten entries; never use pencil or correction fluid.
- Any corrections must be made using a single line strike-through, signed, dated, and justified.
- Electronic data shall be reviewed using audit trails, reviewer comments, and version histories.
5.3 Electronic System Controls
- Access to analytical instruments, LIMS, and CDS shall be restricted via unique user IDs and passwords.
- System administrators must maintain access level logs and periodically review them.
- Audit trails shall be enabled for all critical data actions including acquisition, modification, and deletion.
- Perform daily backup of all electronic data and store copies in secure, validated repositories.
5.4 Sample and Reagent Traceability
- Label all reagents, samples, and solutions with:
- Name, concentration, preparation date, expiry date, and prepared by
- Track sample movement using Annexure-1: Sample Movement Log.
5.5 Training and Awareness
- All personnel shall receive annual training on data integrity principles and documentation practices.
- Training records shall be maintained as per Annexure-2: Training Record Log.
5.6 Deviation and Investigation Management
- Any suspected data manipulation, backdating, or falsification must be immediately reported to QA.
- QA shall investigate and document findings using Annexure-3: Data Integrity Incident Form.
- Corrective and Preventive Actions (CAPA) must be initiated and tracked to closure.
5.7 Data Retention and Archival
- Retain raw data, audit trails, logbooks, and reports for a minimum of 5 years or as per regulatory requirements.
- Archived data should be stored in a manner that prevents tampering, loss, or degradation.
6. Abbreviations
- BA/BE: Bioavailability/Bioequivalence
- LIMS: Laboratory Information Management System
- CDS: Chromatography Data System
- GDP: Good Documentation Practice
- CAPA: Corrective and Preventive Action
- QA: Quality Assurance
7. Documents
- Sample Movement Log – Annexure-1
- Training Record Log – Annexure-2
- Data Integrity Incident Form – Annexure-3
8. References
- MHRA GxP Data Integrity Guidance
- FDA 21 CFR Part 11
- ICH Q10: Pharmaceutical Quality System
- WHO TRS No. 996, Annex 5 – Data Integrity
9. SOP Version
Version: 2.0
10. Approval Section
| Prepared By | Checked By | Approved By | |
|---|---|---|---|
| Signature | |||
| Date | |||
| Name | |||
| Designation | |||
| Department |
11. Annexures
Annexure-1: Sample Movement Log
| Sample ID | Date | From Location | To Location | Moved By | Verified By |
|---|---|---|---|---|---|
| PL-212 | 15/04/2025 | Freezer -20°C | LC-MS Lab | Rajesh Kumar | Sunita Reddy |
Annexure-2: Training Record Log
| Employee Name | Training Topic | Date | Trainer | Remarks |
|---|---|---|---|---|
| Ajay Verma | Data Integrity in BA/BE | 10/03/2025 | QA Officer | Completed |
Annexure-3: Data Integrity Incident Form
| Incident ID | Date | Reported By | Description | Investigation Summary | CAPA Reference |
|---|---|---|---|---|---|
| DI-001 | 14/04/2025 | QA Auditor | Backdated chromatogram found | Confirmed by audit trail | CAPA-009 |
Revision History:
| Revision Date | Revision No. | Details | Reason | Approved By |
|---|---|---|---|---|
| 01/01/2022 | 1.0 | Initial Release | New SOP | QA Head |
| 17/04/2025 | 2.0 | Expanded ALCOA+ framework and annexures added | Regulatory Update | QA Head |